BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) has been assigned an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among […]
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Rating) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02, Briefing.com reports. The company had revenue of $68.80 million for the quarter, compared to the consensus estimate of $71.44 million. The business’s […]
Should You Buy or Sell BioCryst Pharmaceuticals Stock? Get The Latest BCRX Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
Needham & Company LLC restated their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Rating) in a research note issued to investors on Thursday morning, Benzinga reports. The firm currently has a $14.00 price target on the biotechnology company’s stock. BCRX has been the topic of a number of other research reports. JMP […]
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) has received an average recommendation of “Moderate Buy” from the eleven analysts that are presently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokerages […]